News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
422,540 Results
Type
Article (33845)
Company Profile (49)
Press Release (388634)
Multimedia
Podcasts (97)
Webinars (8)
Section
Business (133408)
Career Advice (1345)
Deals (24291)
Drug Delivery (131)
Drug Development (60329)
Employer Resources (105)
FDA (10419)
Job Trends (9168)
News (213512)
Policy (25800)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (4)
Academia (1881)
Accelerated approval (52)
ADA (31)
Adcomms (32)
Allergies (152)
Alliances (42414)
ALS (156)
Alzheimer's disease (1496)
Antibody-drug conjugate (ADC) (411)
Approvals (10673)
Artificial intelligence (487)
ASCO (226)
Autoimmune disease (228)
Automation (34)
Bankruptcy (240)
Best Places to Work (7692)
BIO (44)
BIOSECURE Act (16)
Biosimilars (199)
Biotechnology (39)
Bladder cancer (152)
Brain cancer (76)
Breast cancer (555)
Cancer (4675)
Cardiovascular disease (368)
Career advice (1160)
Career pathing (30)
CAR-T (239)
CDC (71)
Cell therapy (679)
Cervical cancer (40)
Clinical research (52524)
Collaboration (1854)
Company closure (5)
Compensation (1316)
Complete response letters (89)
COVID-19 (2637)
CRISPR (84)
C-suite (614)
Cystic fibrosis (96)
Data (6265)
Decentralized trials (2)
Denatured (13)
Depression (135)
Dermatology (75)
Diabetes (512)
Diagnostics (3921)
Digital health (35)
Diversity (9)
Diversity, equity & inclusion (34)
Drug discovery (265)
Drug pricing (192)
Drug shortages (32)
Duchenne muscular dystrophy (268)
Earnings (44258)
Editorial (68)
Employer branding (13)
Employer resources (101)
Events (50317)
Executive appointments (514)
FDA (13361)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (28)
Funding (1199)
Gene editing (179)
Generative AI (50)
Gene therapy (599)
GLP-1 (1077)
Government (4477)
Grass and pollen (6)
Guidances (330)
Healthcare (11532)
Hematology (142)
HIV (73)
Huntington's disease (54)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (90)
Immunology and inflammation (224)
Immuno-oncology (85)
Indications (167)
Infectious disease (2991)
Inflammatory bowel disease (142)
Inflation Reduction Act (11)
Influenza (139)
Intellectual property (206)
Interviews (236)
IPO (10586)
IRA (47)
Job creations (1761)
Job search strategy (967)
JPM (46)
Kidney cancer (15)
Labor market (67)
Layoffs (358)
Leadership (28)
Legal (7108)
Liver cancer (77)
Longevity (34)
Lung cancer (637)
Lymphoma (367)
Machine learning (41)
Management (34)
Manufacturing (819)
Marketing (4)
MASH (186)
Medical device (6189)
Medtech (6257)
Mergers & acquisitions (14763)
Metabolic disorders (1430)
mRNA (206)
Multiple sclerosis (141)
NASH (21)
Neurodegenerative disease (360)
Neuropsychiatric disorders (91)
Neuroscience (2719)
Neurotech (1)
NextGen: Class of 2026 (3672)
Non-profit (2814)
Now hiring (12)
Obesity (721)
Opinion (273)
Ovarian cancer (167)
Pain (160)
Pancreatic cancer (279)
Parkinson's disease (298)
Partnered (26)
Patents (403)
Patient recruitment (480)
Peanut (53)
People (26261)
Pharmaceutical (16)
Pharmacy benefit managers (22)
Phase 1 (15847)
Phase 2 (22841)
Phase 3 (18518)
Pipeline (7508)
Policy (327)
Postmarket research (1851)
Preclinical (6587)
Press Release (28)
Prostate cancer (250)
Psychedelics (55)
Radiopharmaceuticals (289)
Rare diseases (959)
Real estate (2619)
Recruiting (49)
Regulatory (19043)
Reports (27)
Research institute (1655)
Resumes & cover letters (199)
Rett syndrome (43)
RNA editing (14)
RSV (91)
Schizophrenia (153)
Series A (169)
Series B (130)
Service/supplier (2)
Sickle cell disease (82)
Special edition (16)
Spinal muscular atrophy (159)
Sponsored (31)
Startups (1938)
State (1)
Stomach cancer (14)
Supply chain (102)
Tariffs (74)
The Weekly (83)
Vaccines (1172)
Venture capital (88)
Weight loss (489)
Women's health (82)
Worklife (13)
Date
Today (52)
Last 7 days (269)
Last 30 days (1395)
Last 365 days (19958)
2026 (10849)
2025 (19922)
2024 (22346)
2023 (25266)
2022 (33400)
2021 (35902)
2020 (34107)
2019 (27913)
2018 (21235)
2017 (20189)
2016 (18714)
2015 (21498)
2014 (15968)
2013 (12890)
2012 (13639)
2011 (14423)
2010 (13094)
Location
Africa (588)
Alabama (58)
Alaska (3)
Arizona (142)
Arkansas (6)
Asia (27587)
Australia (4931)
California (8623)
Canada (2507)
China (1083)
Colorado (339)
Connecticut (413)
Delaware (309)
Europe (66343)
Florida (1330)
Georgia (268)
Hawaii (4)
Idaho (31)
Illinois (674)
India (75)
Indiana (416)
Iowa (19)
Japan (485)
Kansas (84)
Kentucky (33)
Louisiana (35)
Maine (36)
Maryland (1193)
Massachusetts (6091)
Michigan (195)
Minnesota (305)
Mississippi (1)
Missouri (96)
Montana (21)
Nebraska (12)
Nevada (92)
New Hampshire (29)
New Jersey (2529)
New Mexico (16)
New York (2451)
North Carolina (1016)
North Dakota (6)
Northern California (4464)
Ohio (235)
Oklahoma (11)
Oregon (14)
Pennsylvania (1715)
Puerto Rico (18)
Rhode Island (19)
South America (810)
South Carolina (42)
South Dakota (1)
Southern California (3388)
Tennessee (116)
Texas (1151)
United States (30281)
Utah (194)
Vermont (2)
Virginia (228)
Washington D.C. (44)
Washington State (666)
West Virginia (2)
Wisconsin (83)
Wyoming (2)
422,540 Results for "itm isotopen technologien muenchen ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
June 29, 2026
·
6 min read
Press Releases
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
July 7, 2026
·
5 min read
Press Releases
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026
June 1, 2026
·
4 min read
Press Releases
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
June 1, 2026
·
4 min read
Press Releases
ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium
May 19, 2026
·
3 min read
Press Releases
ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
March 5, 2026
·
5 min read
Press Releases
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
April 21, 2026
·
2 min read
Press Releases
ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma
November 17, 2025
·
4 min read
Funding
NewLimit snags $435M after seeing age reversal in human liver cells
NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells.
June 3, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
DeepoMe Introduces the First Biomedical World Model for Chronic Disease Management and Aging Intervention
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging
May 26, 2026
·
1 min read
1 of 42,254
Next
